Wade Iams

Clinical trials

• A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis

  Principal investigator · Withdrawn · Phase 1, Phase 2

  Criterium, Inc.

  2022–2023
• Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

  Site PI · Recruiting · Phase 3

  ImmunityBio, Inc.

  2025–2029
• Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  Site PI · Recruiting · Phase 3

  Eli Lilly and Company

  2025–2032
• A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  Site PI · Recruiting · Phase 3

  Eli Lilly and Company

  2023–2031